Details for New Drug Application (NDA): 211763
✉ Email this page to a colleague
The generic ingredient in NADOLOL is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.
Pharmacology for NDA: 211763
Mechanism of Action | Adrenergic beta-Antagonists |
Medical Subject Heading (MeSH) Categories for 211763
Suppliers and Packaging for NDA: 211763
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
NADOLOL | nadolol | TABLET;ORAL | 211763 | ANDA | Alembic Pharmaceuticals Limited | 46708-402 | 46708-402-30 | 30 TABLET in 1 BOTTLE (46708-402-30) |
NADOLOL | nadolol | TABLET;ORAL | 211763 | ANDA | Alembic Pharmaceuticals Limited | 46708-402 | 46708-402-31 | 100 TABLET in 1 BOTTLE (46708-402-31) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
Approval Date: | Jun 2, 2023 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 40MG | ||||
Approval Date: | Jun 2, 2023 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 80MG | ||||
Approval Date: | Jun 2, 2023 | TE: | AB | RLD: | No |
Complete Access Available with Subscription